Connor, Clark & Lunn Investment Management (CC&L)
GNMX

Connor, Clark & Lunn Investment Management (CC&L)’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,500
Closed -$49K – 1012
2017
Q1 		$49K Buy
+26,500
New +$120K ﹤0.01% 872

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GNMX Position: Q2 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 26,500 shares — an estimated $49K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GNMX in Q1 2017 and held it in 1 quarter. The position peaked at $49K in Q1 2017. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,500 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $49K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aevi Genomic Medicine Inc in Q1 2017 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Aevi Genomic Medicine Inc position peaked at $49K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2017, filed 14 Aug 2017.